MedPacto, Inc.
Develops first-in-class therapies for oncology and autoimmune diseases.
235980 | KO
Overview
Corporate Details
- ISIN(s):
- KR7235980000
- LEI:
- Country:
- South Korea
- Address:
- 서울특별시 서초구 명달로 92, 보림빌딩, 서초구
- Website:
- http://www.medpacto.com/eng/
- Sector:
- Manufacturing
Description
MedPacto, Inc. is a clinical-stage biotechnology company specializing in the discovery and development of first-in-class therapies. The company leverages a biomarker-driven and genome-based platform to create personalized treatments, aiming to advance precision medicine. Its primary therapeutic areas include oncology and autoimmune diseases, with pipeline expansion into metabolic and bone joint disorders. MedPacto's research focuses on novel mechanisms, such as modulating the tumor microenvironment, to address incurable diseases and overcome the limitations of existing treatments.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2019-12-13 00:00 |
증권발행실적보고서
|
Korean | 39.7 KB | ||
| 2019-12-05 00:00 |
투자설명서
|
Korean | 2.0 MB | ||
| 2019-11-07 00:00 |
분기보고서 (2019.09)
|
Korean | 720.8 KB | ||
| 2019-11-07 00:00 |
증권신고서(지분증권)
|
Korean | 1.9 MB | ||
| 2019-08-13 00:00 |
반기보고서 (2019.06)
|
Korean | 756.6 KB | ||
| 2019-04-10 00:00 |
감사보고서 (2018.12)
|
Korean | 295.5 KB |
Automate Your Workflow. Get a real-time feed of all MedPacto, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for MedPacto, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for MedPacto, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
